| 11.07.2025 09:45 | GSK, NWG, LMP | LONDON BROKER RATINGS: Jet2 raised to 'buy'; Investec cuts Pagegroup | Alliance |
| 11.07.2025 07:00 | GSK | Transaction in Own Shares | RNS |
| 10.07.2025 07:00 | GSK | Transaction in Own Shares | RNS |
| 09.07.2025 07:00 | GSK | Transaction in Own Shares | RNS |
| 08.07.2025 07:00 | GSK | Transaction in Own Shares | RNS |
| 07.07.2025 16:00 | GSK | GSK completes acquisition of efimosfermin for SLD | RNS |
| 07.07.2025 07:00 | GSK | Transaction in Own Shares | RNS |
| 04.07.2025 07:00 | GSK | Transaction in Own Shares | RNS |
| 03.07.2025 16:44 | VTA, POLR, KITW | UK dividends calendar - next 7 days | Alliance |
| 03.07.2025 07:00 | GSK | Transaction in Own Shares | RNS |
| 02.07.2025 07:00 | GSK | Transaction in Own Shares | RNS |
| 01.07.2025 15:00 | GSK | Total Voting Rights | RNS |
| 01.07.2025 07:00 | GSK | Transaction in Own Shares | RNS |
| 30.06.2025 09:38 | TLW, KOS, ZEG | LONDON BROKER RATINGS: Babcock International price targets raised | Alliance |
| 30.06.2025 07:00 | GSK | Transaction in Own Shares | RNS |
| 27.06.2025 07:00 | GSK | Transaction in Own Shares | RNS |
| 26.06.2025 07:00 | GSK | Transaction in Own Shares | RNS |
| 25.06.2025 07:00 | GSK | Transaction in Own Shares | RNS |
| 24.06.2025 15:30 | GSK | Director/PDMR Shareholding | RNS |
| 24.06.2025 15:00 | GSK | Director Declaration | RNS |
| 24.06.2025 07:00 | GSK | Transaction in Own Shares | RNS |
| 23.06.2025 17:50 | GSK | Replacement - Director/PDMR Shareholding | RNS |
| 23.06.2025 15:30 | GSK | Director/PDMR Shareholding | RNS |
| 23.06.2025 09:55 | GSK | GSK drug to treat itch caused by liver disease accepted for EU review | Alliance |
| 23.06.2025 08:30 | GSK | Replacement RNS: Linerixibat file accepted by EMA | RNS |
| 23.06.2025 08:18 | GSK | GSK Submits Arexvy for adults 18+ with EMA | RNS |
| 23.06.2025 07:00 | GSK | Transaction in Own Shares | RNS |
| 20.06.2025 08:27 | GSK | Japan accepts GSK application for expanded use of RSV vaccine Arexvy | Alliance |
| 20.06.2025 07:00 | GSK | Arexvy filed in Japan for 18-49 at increased risk | RNS |
| 20.06.2025 07:00 | GSK | Transaction in Own Shares | RNS |
| 19.06.2025 07:00 | GSK | Transaction in Own Shares | RNS |
| 18.06.2025 07:00 | GSK | Transaction in Own Shares | RNS |
| 17.06.2025 12:36 | BME, 1SN, GSK | DIRECTOR DEALINGS: New B&M CEO Tjeerd Jegen buys GBP500,000 in shares | Alliance |
| 17.06.2025 07:00 | GSK | Transaction in Own Shares | RNS |
| 16.06.2025 07:00 | GSK | Transaction in Own Shares | RNS |
| 13.06.2025 15:30 | GSK | Director/PDMR Shareholding | RNS |
| 13.06.2025 08:14 | GSK | GSK's RSV drug Arexvy accepted for regulatory review in Europe | Alliance |
| 13.06.2025 07:00 | GSK | Transaction in Own Shares | RNS |
| 13.06.2025 07:00 | GSK | GSK submits Arexvy for adults 18+ with EMA | RNS |
| 12.06.2025 13:28 | CER, SCE, CMCL | DIRECTOR DEALINGS: Cerillion CEO seeks to sell GBP20 million in shares | Alliance |
| 12.06.2025 07:00 | GSK | Transaction in Own Shares | RNS |
| 11.06.2025 15:30 | GSK | Director/PDMR Shareholding | RNS |
| 11.06.2025 07:00 | GSK | Transaction in Own Shares | RNS |
| 10.06.2025 07:00 | GSK | Transaction in Own Shares | RNS |
| 09.06.2025 07:00 | GSK | Transaction in Own Shares | RNS |
| 06.06.2025 07:00 | GSK | Transaction in Own Shares | RNS |
| 05.06.2025 07:00 | GSK | Transaction in Own Shares | RNS |
| 04.06.2025 08:07 | GSK | IN BRIEF: GSK launches second tranche of GBP2 billion share buyback | Alliance |
| 04.06.2025 07:00 | GSK | GSK - second tranche of share buyback programme | RNS |
| 04.06.2025 07:00 | GSK | Transaction in Own Shares | RNS |
| 03.06.2025 09:28 | FORT, POLR, LIO | LONDON BROKER RATINGS: Jefferies raises Hiscox, cuts Rio Tinto | Alliance |
| 03.06.2025 07:00 | GSK | Transaction in Own Shares | RNS |
| 02.06.2025 21:45 | SAA, KGF, GSK | DIRECTOR DEALINGS: hVIVO CEO buys shares; Investec execs sell stock | Alliance |
| 02.06.2025 15:30 | GSK | Director/PDMR Shareholding | RNS |
| 02.06.2025 15:00 | GSK | Total Voting Rights | RNS |
| 02.06.2025 08:29 | GSK | US FDA accepts new drug application for GSK's liver drug linerixibat | Alliance |
| 02.06.2025 07:00 | GSK | Linerixibat file accepted for review by US FDA | RNS |
| 02.06.2025 07:00 | GSK | Transaction in Own Shares | RNS |
| 30.05.2025 07:00 | GSK | Transaction in Own Shares | RNS |
| 29.05.2025 07:00 | GSK | Transaction in Own Shares | RNS |
| 28.05.2025 12:16 | GSK | GSK ends cUTI trial early as Spero joint product meets efficacy goal | Alliance |
| 28.05.2025 12:00 | GSK | GSK stops Phase 3 trial on cUTIs for efficacy | RNS |
| 28.05.2025 07:00 | GSK | Transaction in Own Shares | RNS |
| 27.05.2025 07:00 | GSK | Transaction in Own Shares | RNS |
| 23.05.2025 12:49 | GSK | GSK hails positive EU opinion of blood cancer treatment Blenrep | Alliance |
| 23.05.2025 12:16 | GSK | positive CHMP opinion on Blenrep in EU | RNS |
| 23.05.2025 08:27 | GSK | GSK's Nucala wins FDA approval for COPD with eosinophilic inflammation | Alliance |
| 23.05.2025 07:00 | GSK | FDA approves Nucala COPD indication | RNS |
| 23.05.2025 07:00 | GSK | Transaction in Own Shares | RNS |
| 22.05.2025 07:00 | GSK | Transaction in Own Shares | RNS |
| 21.05.2025 07:00 | GSK | Transaction in Own Shares | RNS |
| 20.05.2025 15:30 | GSK | Director/PDMR Shareholding | RNS |
| 20.05.2025 07:00 | GSK | Transaction in Own Shares | RNS |
| 19.05.2025 08:20 | GSK | GSK wins approval in Japan for Blenrep combination as myeloma therapy | Alliance |
| 19.05.2025 07:00 | GSK | Blenrep for 2L+ multiple myeloma approved in Japan | RNS |
